Skip to content

A clinical study of dual target and multi course burst transcranial magnetic stimulation in the treatment of dyskensia in Parkinson' disease

A clinical study of dual target and multi course burst transcranial magnetic stimulation in the treatment of dyskensia in Parkinson' disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037373
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson 's disease

Interventions

Intervention :TBS mode rTMS
control:TBSmode sham stimulation rTMS

Sponsors

Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)Patients at age between 40 and 75 years old. 2) patients have been clinically diagnosed with PD according to the 2015 International MDS PD criteria. 3) patients whose symptoms have been well controlled in the condition of stable dopaminergic treatment for at least 1 month before the recruitment. 4) patients that have obvious dyskinesia (MDS-UPDRS-IV item 2 score is above 2 points and MDS-UPDRS-IV item 1 score is above 2 points). 5) patients or their legal guardians have agreed to participate the study and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women; 2) patients that have severe cognitive impairment or psychiatric symptoms; 3) patients that have severe liver and kidney impairment; 4) patients that have been participating the other clinical studies or participated other clinical studies within the previous 30 days at the recruitment; 5) patients that are unable to cooperate with the assessments; 6)patients with metal foreign bodies in the heads or pacemakers or cochlear implants.

Design outcomes

Primary

MeasureTime frame
the difference value between the CAPSIT score at baseline and CAPSIT score after the initiation of the intervention;

Secondary

MeasureTime frame
the difference value between the daily levodopa dosage and levodopa equivalent dosage at baseline and the daily levodopa dosage and levodopa equivalent dosage after initiation o the intervention;the difference value between the PD-NMSQ30 score at baseline and PD-NMSQ30 score after initiation o the intervention;the change between the activated brain areas and network at baseline and after the intervention;the change between the F18-FDG brain metabolism at baseline and the F18-FDG metabolism after the intervention;the association between the polymorphism of NMDA and BDNFgenes and the dyskinesia of PD;the difference value between the PDQ-8 score at baseline and the PDQ-8 score after intervention;the change between the tremor the parameters of the electromyography at baseline and the parameters of tremor electromyograhpy after intervention;the difference value between CGI score at baseline and CGI score after intervention;

Countries

China

Contacts

Public ContactZhenguo Liu

Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine

zhenguoliu2004@aliyun.com+86 21-25077501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026